[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antidepressive-agents\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antidepressive-agents":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100504026","patient-centred-deprescribing-of-psychotropic-sedative-and-anticholinergic-medication-in-elderly-patients-with-polypharmacy-100504026",false,"NCT05842928","Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy","Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy: a Cluster-randomised Trial","PARTNER","Inclusion Criteria:\n\n* Aged 65 years or older\n* Patient is capable of giving consent\n* GP contact in the quarter prior to inclusion\n* Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months\n* Willingness to select a regular pharmacy for the study period\n* Consent to data exchange between GP and community pharmacy\n\nExclusion Criteria:\n\n* Terminal illness (life expectancy \\\u003C 6 months)\n* Current treatment of pain associated with cancer\n* Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment)\n* Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)\n* Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity)\n* Current participation in research projects on medication safety or geriatric medicine","ALL","65 Years",{"count":20,"type":21},352,"ESTIMATED","INTERVENTIONAL",[24],"NA","The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag\u002Fmedication review and patient empowerment, (4) GP practice visit with shared decision making. The control intervention only comprises a pharmacy visit with brown bag review.",[27,28,29,30,31,32],"Deprescriptions","Antidepressive Agents","Antipsychotic Agents","Analgesics, Opioid","Hypnotics and Sedatives","Cholinergic Antagonists",[34,35,36,37,38],"Polypharmacy","General Practice","Primary Health Care","Pharmacies","Medication Safety","RECRUITING","2025-04-30",{"date":42,"type":43},"2025-05-04","ACTUAL",{"date":45,"type":43},"2023-03-25",{"date":47,"type":21},"2026-10",{"name":49,"class":50},"Ludwig-Maximilians - University of Munich","OTHER",3,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100486629","precision-medicine-in-the-depression-treatment-100486629","NCT05616559","Precision Medicine in the Depression Treatment","The BrainDrugs-Depression Study: A Prospective Precision Psychiatry Cohort Study in the Treatment of Depression","BDD","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Fulfilment of International Classification of Diseases version 10 diagnostic criteria for a primary depressive episode (i.e., not secondary to known organic or other psychiatric disorder).\n* Referral to a treatment package for single-episode depression.\n\nExclusion Criteria:\n\n* Psychosis or psychotic symptoms\n* History of severe head trauma\n* Somatic disease associated with morphological brain changes (e.g., brain tumour)\n* Insufficient Danish language skills to complete questionnaires and cognitive testing\n\nAdditional exclusion criteria for Cohort II:\n\n* Severe somatic disease\n* Contraindications for MRI (e.g., metal implants, claustrophobia or back problems)\n\nAdditional exclusion criteria for Cohort III:\n\n* Severe somatic disease\n* Contraindications for MRI\n* Exposure to radioactivity \\>10 mSv within the last year\n* Pregnancy or breastfeeding\n* Use of psychotropic drugs","18 Years",{"count":62,"type":21},800,"18 Months","OBSERVATIONAL","The BrainDrugs-D study uses multimodal neuroimaging combined with self-report measures, clinical and molecular markers to identify clinically relevant predictors that can identify subtypes of major depressive disorder (MDD) and, in a naturalistic setting, predict treatment response to standard antidepressive treatment. The cohorts are followed in nationwide health registries.",[67,68,69,70,28],"Depressive Disorder, Major","Treatment Outcome","Cognitive Dysfunction","Cognitive Behavioral Therapy",[72,73,74,75,76,77,78,79,80,81,82,83],"PET","MRI","fMRI","EEG","Prediction of treatment response","Early life stress","Selective Serotonin Reuptake Inhibitor","Psychometrics","MDD","Cold cognition","Social cognition","Anxiety","2024-10-03",{"date":86,"type":43},"2024-10-08",{"date":88,"type":43},"2021-06-15",{"date":90,"type":21},"2026-12",{"name":92,"class":50},"Rigshospitalet, Denmark",1]